Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EllaOne Firm Endorses UK Reproductive Rights Group's Push For OTC Sales Of Emergency Contraceptives

Executive Summary

EllaOne manufacturer HRA Pharma supports British Pregnancy Advisory Service's call to scrap mandatory consultations for emergency contraceptives by switching the medicines from pharmacy-only sales to OTC. BPAS says there are “no risks which outweigh its use and it is considerably safer than many medicines sold straight from the shelf in the UK."

You may also be interested in...



Court Ruling Compels Emergency Contraceptives Over The Counter

Under a federal judge’s order, FDA must reverse its denial of the Center for Reproductive Rights’ 12-year-old citizen petition and allow universal OTC access to Plan B One-Step and equivalent levonorgestrel-based emergency contraceptives within 30 days.

Stada’s Natures Aid Launches Children’s Supplement Range In UK

Stada Arzneimittel's UK Natures Aid subsidiary adds a new, fun line of children's VMS products to its portfolio. 

CPHI Podcast Special: The Supplements Market – From Slump to Surge

In this podcast special, HBW Insight senior editor David Ridley is interviewed by CPHI's Rebecca Lumley about the latest trends in the European dietary supplements space. They discuss which products surged in popularity during the pandemic, the rise of self-care and the current regulatory environment in Europe.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel